Header cover image
  • Investing Ideas
  • /
  • Australian Pharmaceuticals & Biotech Undervalued based on future growth

Australian Pharmaceuticals & Biotech Undervalued based on future growth

Results

1

1 new

Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)

1 companies

EZZ Life Science Holdings

Market Cap: AU$96.7m

Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and internationally.

New

EZZ

AU$2.08

7D

-4.6%

1Y

17.5%